Clinical trials: Oral Phase
Healthy Volunteers
Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 in Healthy Volunteers
The primary aim of this study is to investigate the safety and tolerability of AZD2423 single doses in healthy volunteers.
- Trial name
- SAD (NCT00940212)
- Testing
- AZD2423
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Relapsing Remitting Multiple Sclerosis
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
To determine the efficacy and safety of an oral drug (BGC20-0134) in patients with relapsing remitting multiple sclerosis. Specifically, the cumulative number of new gadolinium enhancing lesions after 24 weeks of treatment with…
- Trial name
- NCT01037907
- Testing
- Pleneva TM BGC20-0134
- Where
- 35 sites in Belgium, France and 4 more
- Volunteers
- 173 people
- Sponsor
- Boston Scientific Corporation
Abuse Potential
Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience
This will be a randomized, double-blind, double-dummy, placebo- and active controlled, 5 treatment, 10 sequence, 5 period crossover single dose, Williams square design study in healthy adult, non drug dependent male and female…
- Trial name
- NCT04570436
- Testing
- gabapentin 600 mg, gabapentin 1200 mg, gabapentin 1800 mg
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Viatris Specialty LLC
Carcinoma, Basal Cell
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
This study is to determine the recommended phase II dose (RP2D) and schedule of CX-4945 when administered orally twice daily for 28 consecutive days, in a 4-week (28 days) cycle, in patients with locally advanced or metastatic…
- Trial name
- NCT03897036
- Testing
- CX-4945
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Senhwa Biosciences, Inc.
Insomnia
the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 Tablets
Multiple Dose Safety, Tolerability, PK ，PD and Food Effect Study of HEC83518 in Healthy Subjects
- Trial name
- NCT04667429
- Testing
- Food, HEC83518
- Where
- China
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Attention-deficit Hyperactivity Disorder
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder
This is a phase 1b, multicenter, open-label, multiple-dose trial in pediatric subjects (4 - 12 years of age, inclusive) with a confirmed diagnosis of ADHD.
- Trial name
- NCT04786730
- Testing
- Centanafadine
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Multiple Myeloma
Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this Phase 1 study is to characterize the pharmacokinetic (PK) and tolerability of oral ixazomib (MLN9708) when administered in combination with lenalidomide and dexamethasone in adult Asian participants with…
- Trial name
- NCT01645930
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 5 sites in Hong Kong, Singapore and 1 more
- Volunteers
- 43 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Healthy
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KRP-A218 in Healthy Subjects
This first-in-human study has three parts. In Parts A and B, the safety, tolerability, and pharmacokinetics (PK) will be evaluated following administration of single and multiple doses of KRP-A218, including food-effect.
- Trial name
- NCT04908800
- Testing
- KRP-A218, itraconazole
- Where
- United Kingdom
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Kyorin Pharmaceutical Co.,Ltd
Gout
The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject
XNW3009 is a small molecule hURAT1 inhibitor developed independently by Sinovent Pty Ltd., and is intended to treat gout-related hyperuricemia.
- Trial name
- NCT04040907
- Testing
- XNW3009
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Evopoint Biosciences Inc.
Hepatic Impairment
Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects
This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of seladelpar following administration of a single oral dose in subjects with varying degrees of hepatic impairment (HI)…
- Trial name
- NCT03369002
- Testing
- seladelpar
- Where
- 4 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Healthy
A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants
The main purpose of this study is to evaluate the effect of intravenous (IV) infusions of piperacillin/tazobactam on the pharmacokinetics (PK) of JNJ-63549109 after a single oral dose of lumicitabine in healthy adult participants.
- Trial name
- NCT03441529
- Testing
- Lumicitabine, Piperacillin/Tazobactam
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Volunteers
A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine
The purpose of this trial is to assess relative bioavailability of centanafadine (CTN) SR tablet to CTN QD XR capsule in healthy adult participants.
- Trial name
- NCT07465731
- Testing
- Centanafadine SR, Centanafadine QD XR
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Advanced Solid Tumors or Lymphomas
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
CA-170 is a rationally designed and orally available, small molecule that directly targets the Programmed death-ligands 1 and 2 (PD-L1/PD-L2), and V-domain Ig suppressor of T cell activation (VISTA) immune checkpoints and results…
- Trial name
- NCT02812875
- Testing
- CA-170
- Where
- 20 sites in United States, South Korea and 2 more
- Volunteers
- 71 people
- Sponsor
- Curis, Inc.
Healthy Volunteer
Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response
The purpose of this study is to evaluate the potential effect of ozanimod on pressor response when co-administered with oral tyramine in healthy adult subjects.
- Trial name
- NCT03694119
- Testing
- Phenelzine, Tyramine, ozanimod
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Celgene
Erectile Dysfunction
Effect of Moderate Alcohol on Absorption and Onset of Hezkue Sildenafil Suspension
This is a Phase 2, open-label, randomized crossover study assessing the effect of moderate alcohol intake on the absorption and onset of action of Hezkue® sildenafil oral suspension in adult subjects.
- Trial name
- NCT07290400
- Testing
- Hezkue Sildenafil Oral Suspension, Moderate Alcohol Intake
- Volunteers
- 36 people
- Sponsor
- Aspargo Labs, Inc
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
The purpose of this study is to determine the safety, tolerability, and the highest dose of GC4419 that can be given to patients with squamous cell cancer of the head and neck who are receiving standard radiation therapy and…
- Trial name
- NCT01921426
- Testing
- GC4419
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Galera Therapeutics, Inc.
Healthy Adult Subjects
Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of ID110521156 in healthy adult subjects. This is the first clinical study of ID110521156.
- Trial name
- NCT06063291
- Testing
- ID110521156
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
BRAF or NRAS Mutant Metastatic Melanoma
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.
- Trial name
- NCT01320085
- Testing
- MEK162
- Where
- 25 sites in United States, Germany and 3 more
- Volunteers
- 183 people
- Sponsor
- Pfizer
Neoplasms, Breast Neoplasms
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
This study is comprised of two portions: a Phase 1 portion and a Phase 2 portion. The Phase 1 portion is a single-country, non-randomized, open label, clinical trial which will evaluate the safety, tolerability, preliminary…
- Trial name
- NCT01684215
- Testing
- PD-0332991, letrozole
- Where
- 16 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Pfizer
Sjögren Syndrome
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
This was an adaptive design phase 2 study to establish safety and efficacy; and to characterize the dose-response of LOU064 in subjects with moderate to severe Sjögren's syndrome.
- Trial name
- LOUiSSe (NCT04035668)
- Testing
- Remibrutinib
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.